Evaluating Cancer of the Central Nervous System Through Next-Generation Sequencing of Cerebrospinal Fluid [BIOLOGY OF NEOPLASIA]
Conclusion
The study shows that CSF harbors clinically relevant genomic alterations in patients with CNS cancers and should be considered for liquid biopsies to monitor tumor evolution in the CNS. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 30, 2016 Category: Cancer & Oncology Authors: Pentsova, Shah, Tang, Boire, You, Briggs, Omuro, Lin, Fleisher, Grommes, Panageas, Meng, Selcuklu, Ogilvie, Distefano, Shagabayeva, Rosenblum, DeAngelis, Viale, Mellinghoff, Berger Tags: BIOLOGY OF NEOPLASIA Source Type: research
Discussions of Life Expectancy and Changes in Illness Understanding in Patients With Advanced Cancer [Palliative and Supportive Care]
Conclusion
Patients with advanced cancer who report recent discussions of prognosis/life expectancy with their oncologists come to have a better understanding of the terminal nature of their illnesses. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 30, 2016 Category: Cancer & Oncology Authors: Epstein, Prigerson, OReilly, Maciejewski Tags: Prognostic Studies, Supportive Care, Behavioral and Lifestyle Risk Factors, Population and observational studies (SEER, WHI observational, etc.), Epidemiology, Diagnosis & Staging, End of Life, Outcomes Research, Palliative Care, Epidemiology, Diagnosis & Source Type: research
Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma [Melanoma]
Conclusion
Adoptive cell transfer can mediate durable complete regressions in 24% of patients with metastatic melanoma, with median survival > 3 years. Results were similar using chemotherapy preparative regimens with or without addition of TBI. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 30, 2016 Category: Cancer & Oncology Authors: Goff, Dudley, Citrin, Somerville, Wunderlich, Danforth, Zlott, Yang, Sherry, Kammula, Klebanoff, Hughes, Restifo, Langhan, Shelton, Lu, Kwong, Ilyas, Klemen, Payabyab, Morton, Toomey, Steinberg, White, Rosenberg Tags: Translational Oncology, Melanoma, Immunology/Immunobiology Source Type: research
Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Childrens Oncology Group Study AALL0232 [Pediatric Oncology]
Conclusion
High-dose methotrexate is superior to Capizzi methotrexate for the treatment of high-risk B-acute lymphoblastic leukemia, with no increase in acute toxicity. Dexamethasone given during induction benefited younger children but provided no benefit and was associated with a higher risk of osteonecrosis among participants 10 years and older. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 30, 2016 Category: Cancer & Oncology Authors: Larsen, Devidas, Chen, Salzer, Raetz, Loh, Mattano, Cole, Eicher, Haugan, Sorenson, Heerema, Carroll, Gastier-Foster, Borowitz, Wood, Willman, Winick, Hunger, Carroll Tags: Acute Lymphoblastic Leukemia Pediatric Oncology Source Type: research
Minimal Treatment of Low-Risk, Pediatric Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the Children's Oncology Group [Pediatric Oncology]
Conclusion
Some 75% of highly selected pediatric patients with LPHL may be spared chemotherapy after surgical resection alone. Pediatric LPHL has excellent EFS with chemotherapy that is less intensive than standard regimens; > 90% of patients can avoid radiation therapy. The salvage rate for the few relapses is high, with 100% survival overall. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 30, 2016 Category: Cancer & Oncology Authors: Appel, Chen, Buxton, Hutchison, Hodgson, Ehrlich, Constine, Schwartz Tags: Combined Modality, Hodgkin's Disease Pediatric Oncology Source Type: research
Validation of a Prediction Tool for Chemotherapy Toxicity in Older Adults With Cancer [Clinical Trials]
Conclusion
This study externally validated a chemotherapy toxicity predictive model for older adults with cancer. This predictive model should be considered when discussing the risks and benefits of chemotherapy with older adults. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 30, 2016 Category: Cancer & Oncology Authors: Hurria, Mohile, Gajra, Klepin, Muss, Chapman, Feng, Smith, Sun, De Glas, Cohen, Katheria, Doan, Zavala, Levi, Akiba, Tew Tags: Geriatric Oncology Clinical Trials Source Type: research
Prognostic Impact of 21-Gene Recurrence Score in Patients With Stage IV Breast Cancer: TBCRC 013 [Breast Cancer]
Conclusion
The 21-gene RS is independently prognostic for both TTP and 2-year OS in ER–positive/HER2-negative de novo stage IV breast cancer. Prospective validation is needed to determine the potential role for this assay in the clinical management of this patient subset. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 30, 2016 Category: Cancer & Oncology Authors: King, Lyman, Gonen, Voci, De Brot, Boafo, Sing, Hwang, Alvarado, Liu, Boughey, McGuire, Van Poznak, Jacobs, Meszoely, Krontiras, Babiera, Norton, Morrow, Hudis Tags: Diagnosis & Staging, Surgery Breast Cancer Source Type: research
Prognostic Impact of the Combination of Recurrence Score and Quantitative Estrogen Receptor Expression (ESR1) on Predicting Late Distant Recurrence Risk in Estrogen Receptor-Positive Breast Cancer After 5 Years of Tamoxifen: Results From NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-28 and B-14 [Breast Cancer]
Conclusion
For LDR, RS is strongly prognostic in patients with higher quantitative ESR1. Risk of LDR is relatively low for patients with low RS. These results suggest the value of extended tamoxifen therapy merits evaluation in patients with intermediate and high RS with higher ESR1 expression at initial diagnosis. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 30, 2016 Category: Cancer & Oncology Authors: Wolmark, Mamounas, Baehner, Butler, Tang, Jamshidian, Sing, Shak, Paik Tags: Translational Oncology Breast Cancer Source Type: research
West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment [Breast Cancer]
Conclusion
In this prospective trial, patients with enhanced clinical risk and omitted chemotherapy on the basis of RS ≤ 11 had excellent 3-year survival. The substantial discordance observed between traditional prognostic markers and RS emphasizes the need for standardized assessment and supports the potential integration of standardized, well-validated genomic assays such as RS with clinicopathologic prognostic factors for chemotherapy indication in early hormone receptor–positive BC. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 30, 2016 Category: Cancer & Oncology Authors: Gluz, Nitz, Christgen, Kates, Shak, Clemens, Kraemer, Aktas, Kuemmel, Reimer, Kusche, Heyl, Lorenz-Salehi, Just, Hofmann, Degenhardt, Liedtke, Svedman, Wuerstlein, Kreipe, Harbeck Tags: Chemotherapy, Hormonal Therapy, Clinical Trials, Prognostic Studies Breast Cancer Source Type: research
Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naive Chronic Myeloid Leukemia Patients Trial [Hematologic Malignancy]
Conclusion
These final results from the DASISION trial continue to support dasatinib 100 mg once daily as a safe and effective first-line therapy for the long-term treatment of CML-CP. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 30, 2016 Category: Cancer & Oncology Authors: Cortes, Saglio, Kantarjian, Baccarani, Mayer, Boque, Shah, Chuah, Casanova, Bradley-Garelik, Manos, Hochhaus Tags: Clinical Trials, Biological Therapy, Hematologic Hematologic Malignancy Source Type: research
Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer [Rapid Communication]
Conclusion
In men with low-risk prostate cancer, the efficacy of 70 Gy in 28 fractions over 5.6 weeks is not inferior to 73.8 Gy in 41 fractions over 8.2 weeks, although an increase in late GI/genitourinary adverse events was observed in patients treated with H-RT. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 30, 2016 Category: Cancer & Oncology Authors: Lee, Dignam, Amin, Bruner, Low, Swanson, Shah, DSouza, Michalski, Dayes, Seaward, Hall, Nguyen, Pisansky, Faria, Chen, Koontz, Paulus, Sandler Tags: Radiation, Rapid Communications Source Type: research
Making Radiation Therapy for Prostate Cancer More Economical and More Convenient [EDITORIAL]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 30, 2016 Category: Cancer & Oncology Authors: Zietman Tags: Radiation EDITORIAL Source Type: research
Journal Honors Lillian Smyth, MD, MB BCh BAO, MRCPI (Ireland), As Recipient of the 2016 Journal of Clinical Oncology Young Investigator Award [JCO YIA]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 30, 2016 Category: Cancer & Oncology Tags: JCO YIA Source Type: research
Advertising [ONCOLOGY CAREER CENTER]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 30, 2016 Category: Cancer & Oncology Tags: ONCOLOGY CAREER CENTER Source Type: research
Reply to P. Blanchard et al [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 21, 2016 Category: Cancer & Oncology Authors: Murphy, Galloway, Handorf, Egleston, Ridge Tags: CORRESPONDENCE Source Type: research
